FWA
INKT icon

Freedom Wealth Alliance’s MiNK Therapeutics INKT Stock Holding History

Freedom Wealth Alliance’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-332
Closed -$8.66K – 248
2022
Q4 		$8.66K Buy
+332
New +$7.79K 0.01% 300

Other funds holding INKT

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Freedom Wealth Alliance's INKT Position: Q1 2023 in Review

Freedom Wealth Alliance sold out of MiNK Therapeutics (INKT) in Q1 2023, closing a stake of 332 shares — an estimated $8.66K sold.

Freedom Wealth Alliance first reported a position in INKT in Q4 2022 and held it in 1 quarter. The position peaked at $8.66K in Q4 2022. 12 funds tracked by Wall St. Rank hold INKT as of Q1 2023.

  • Freedom Wealth Alliance reported no remaining MiNK Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Freedom Wealth Alliance sold 332 MiNK Therapeutics shares in Q1 2023, an estimated $8.66K.
  • Freedom Wealth Alliance first reported a position in MiNK Therapeutics in Q4 2022 and held it in 1 quarter.
  • Freedom Wealth Alliance's MiNK Therapeutics position peaked at $8.66K in Q4 2022.
  • 12 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2023.

Based on Freedom Wealth Alliance's 13F filing for Q1 2023, filed 25 Apr 2023.